SUBSCRIBE
SUBSCRIBE
News   Business

GlaxoSmithKline Invests 500 Million Euros (US $635M) In French Vaccine Plant

September 29, 2006 | 
1 min read
LONDON, Sept 29 (Reuters) - Europe's biggest drugmaker, GlaxoSmithKline Plc (GSK.L: Quote, Profile, Research), is to invest more than 500 million euros ($636 million) at a new production plant in France to expand vaccine manufacturing capacity.

>>> Discuss This Story

Real estate Europe
GlaxoSmithKline
MORE ON THIS TOPIC
Dashed line from pills isolated on white
Cancer
Ipsen Pulls Cancer Drug Amid Risk of Secondary Malignancies
March 9, 2026
 · 
2 min read
 · 
Tristan Manalac
Illustration of cardboard box filled with office supplies, a computer keyboard, lamp, and a potted plant
Layoff Tracker
Vertex Terminates 20 in Reorganization Push
March 9, 2026
 · 
32 min read
 · 
BioSpace Editorial Staff
Brain tumor medical poster. Cancer, metastasis or benign in the human head or in the nerves, pituitary gland, pineal gland, and membranes that cover the surface of the brain 3D vector illustration
Mergers & acquisitions
Servier Adds to Childhood Brain Tumor Portfolio With $2.5B Day One Buy
March 6, 2026
 · 
1 min read
 · 
Annalee Armstrong
Creative collage illustration of financial business. Two businessmen shaking hands for partners agreement. Conceptual illustration of success deal, corporate ethic, connection.
Cardiovascular disease
Alnylam Unites With Tenaya in Potential $1B+ Pact To Find New Genetic Heart Disease Targets
March 5, 2026
 · 
2 min read
 · 
Heather McKenzie